Evidence map›Paper›PMID 30093713›Full record

ArticleThe pharmacogenomics journal2018

Frequency of vitamin K oxidoreductase complex subunit-1 (VKORC1) polymorphisms and warfarin dose management in patients with venous thromboembolism.

Pınar Akın Kabalak, İsmail Savaş, Nejat Akar, Nalan Demir, Yonca Eğin

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Research and practice in thrombosis and haemostasis · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Pınar Akın KabalakMedical Science University, Atatürk Chest Disease and Surgery Training and Research Hospital, Ankara, Turkey. pinarakinn@yahoo.com.ORCID http://orcid.org/0000-0002-4087-7048
İsmail SavaşDepartment of Chest Disease, Ankara University School of Medicine, Ankara, Turkey.
Nejat AkarDepartment of Pediatrics, TOBB-Economy and Technology University Hospital, Ankara, Turkey.
Nalan DemirDepartment of Intensive Care, Osmangazi University School of Medicine, Eskişehir, Turkey.
Yonca EğinDepartment of Pediatric Molecular Genetics, Ankara University School of Medicine, Ankara, Turkey.
Ankara University · TREskişehir Osmangazi University · TRTOBB University of Economics and Technology · TRUniversity of Health Science · KH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Warfarin works by inhibiting VKORC1, so polymorphisms of this gene modify the required drug dose. The aim of this study is to examine the relation between therapeutic weekly dose of warfarin and C1173T/G1639A polymorphism of VKORC1 in patients with VTE. Seventy-five patients with VTE were enrolled. Weekly warfarin doses and time (day) to reach therapeutic INR were evaluated retrospectively along with VKORC1-C1173T and G1639A alleles. The mean weekly warfarin dose was lower and time to reach therapeutic INR was shorter in homozygote alleles (AA and TT) (p < 0.05). The multivariate regression model was produced, R

Indexed as

AgedAllelesFemaleGenotypeHemorrhageHumansMaleMiddle AgedPolymorphism, Single NucleotideRetrospective StudiesVenous ThromboembolismVitamin K Epoxide ReductasesWarfarinVitamin K Epoxide ReductasesVKORC1 protein, humanWarfarin

Identifiers

PMID30093713
OpenAlexW2886884622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.